Application of a biomarker in the screening and diagnosis of precocious puberty in children

Abstract

The invention provides an application of a biomarker in the preparation of children's precocious puberty screening and diagnosis products; the biomarker includes halcinonide, corticosterone, cortisone, 11-deoxycorticosterone, 11-deoxycortisol , 17α‑hydroxyprogesterone, betasone butyrate, fludrocortisone acetate, methylprednisolone acetate, prednisolone acetate, hydrocortisone valerate, methyltestosterone, One or more of androstenediones. The present invention measures a plurality of children's samples, and the results show that specific compounds have significant differences between healthy children and precocious puberty children, and the P value of T test is less than 0.1, indicating that the contents of these compounds have significant differences. Therefore, these compounds with significant differences can be used as diagnostic markers for early screening and diagnosis of precocious puberty in children.

Description

technical field

[0001] The invention relates to the technical field of detection and analysis, in particular to the application of a biomarker in screening and diagnosis of precocious puberty in children. Background technique

[0002] Precocious puberty (PP) is a sexual developmental disorder characterized by the early onset of sexual maturity. In recent years, domestic and foreign research data have shown that the incidence of precocious puberty in children is on the rise. Precocious puberty has a serious adverse effect on the normal growth and development of children. Children with precocious puberty are often accompanied by premature bone growth, which is more likely to cause children to be low in height in adulthood. . In addition, studies have shown that the occurrence of precocious puberty in children is related to the occurrence of malignant tumors of the reproductive system. Precocious puberty has a significant impact on children's psychology and behavior, which ma...

Images